FAIR VALUE DISCLOSURES (Details)	Jun. 30, 2011 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2011 ChemGenex Pharmaceuticals Limited	Jun. 06, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Mar. 31, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited USD ($)	Jun. 30, 2011 ChemGenex Pharmaceuticals Limited Recurring basis Fair value USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited Recurring basis Fair value USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited Recurring basis Significant Other Observable Inputs (Level 2) USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Jun. 30, 2011 Mesoblast Limited USD ($)	Feb. 28, 2011 Mesoblast Limited USD ($)	Dec. 31, 2010 Mesoblast Limited USD ($)	Jun. 30, 2011 Mesoblast Limited Recurring basis Fair value USD ($)	Dec. 31, 2010 Mesoblast Limited Recurring basis Fair value USD ($)	Jun. 30, 2011 Mesoblast Limited Recurring basis Quoted Prices in Active Markets for Identical Assets (Level 1) USD ($)	Dec. 31, 2010 Mesoblast Limited Recurring basis Quoted Prices in Active Markets for Identical Assets (Level 1) USD ($)	Jun. 30, 2011 Ception USD ($)	Jun. 30, 2011 Ception Recurring basis Fair value USD ($)	Dec. 31, 2010 Ception Recurring basis Fair value USD ($)	Jun. 30, 2011 Ception Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Dec. 31, 2010 Ception Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Jun. 30, 2011 BDC USD ($)	Jun. 30, 2011 BDC Recurring basis Fair value USD ($)	Dec. 31, 2010 BDC Recurring basis Fair value USD ($)	Jun. 30, 2011 BDC Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Dec. 31, 2010 BDC Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Jun. 30, 2011 Gemin X Pharmaceuticals USD ($)	Apr. 30, 2011 Gemin X Pharmaceuticals USD ($)	Jun. 30, 2011 Gemin X Pharmaceuticals Recurring basis Fair value USD ($)	Jun. 30, 2011 Gemin X Pharmaceuticals Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Jun. 30, 2011 Recurring basis Fair value USD ($)	Dec. 31, 2010 Recurring basis Fair value USD ($)	Dec. 31, 2010 Recurring basis Quoted Prices in Active Markets for Identical Assets (Level 1) USD ($)	Dec. 31, 2010 Recurring basis Significant Other Observable Inputs (Level 2) USD ($)	Jun. 30, 2011 Recurring basis Significant Unobservable Inputs (Level 3) USD ($)	Dec. 31, 2010 Recurring basis Significant Unobservable Inputs (Level 3) USD ($)
Financial assets and liabilities carried at fair value and measured on a recurring basis
Percentage of investment (as a percent)			27.60%	27.60%	27.60%						20.00%	7.80%	12.20%
Current assets
Purchase Option for ChemGenex Equity Securities						$ 900,000		$ 984,000	$ 984,000
Long term assets
Investment				64,900,000	56,700,000		0				505,800,000	138,100,000	145,900,000	505,800,000	145,923,000	505,800,000	145,923,000
Investment in convertible note securities	505,800,000	155,808,000						9,885,000		9,885,000
Total assets																																	156,792,000	145,923,000	984,000		9,885,000
Short term liabilities
Letter agreement derivative instrument																																22,078,000				22,078,000
Long term liabilities
Contingent consideration																			105,630,000	102,942,000	105,630,000	102,942,000		33,047,000	32,266,000	33,047,000	32,266,000		97,100,000	98,043,000	98,043,000
Total liabilities																																258,798,000	135,208,000			258,798,000	135,208,000
Undiscounted amount of potential milestone payments due in upcoming years, low end of range																		0					0					0
Undiscounted amount of potential milestone payments due in upcoming years, high end of range																		$ 500,000,000					$ 80,000,000					$ 300,000,000